Youngmi Jung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Youngmi Jung has a total of 242 co-authors. Here are the top co-authors by number of shared publications:
Jieun Kim
Pusan National University
18 shared publicationsSihyung Wang
Department of Integrated Biological Science, College of Natural Science, Pusan National University, Pusan, Republic of Korea, 46241
14 shared publicationsChanbin Lee
Institution of Systems Biology Pusan National University Pusan Republic of Korea
12 shared publicationsJeongeun Hyun
Department of Integrated Biological Science, College of Natural Science, Pusan National University, Pusan, 46241, Korea
12 shared publications- Jinsol Han
Department of Integrated Biological Science, College of Natural Science, Pusan National University, Pusan 46241, Republic of Korea
10 shared publications - Jieun Kim
Institute of System Biology, Pusan National University, Pusan 46241, Republic of Korea
8 shared publications
Latest Publications
- Open Access
- 24 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1741351
Visomitin as a differentiation-inducing therapeutic agent through SYK inhibition in AML
Background: Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by the rapid proliferation of immature myeloblasts and resistance to apoptosis. Overcoming the differentiation block and apoptotic resistance remains a major challenge in AML therapy. Visomitin, a mitochondria-targeted antioxidant, has shown protective effects in other contexts, but its potential in AML has not been explored. Methods: We examined the effects of Visomitin on AML cell differentiation and apoptosis using flowcytometry, including CD11b, CD14 staining and ROS measurement. Western blot analysis of Bcl-2 family proteins and p21/p16/Rb axis. Potential underlying mechanisms were explored through SYK activation. Additionally, primary AML patient samples were tested to assess translational relevance, and in vivo efficacy was evaluated in a xenograft mouse model. Results: Treatment with Visomitin promoted differentiation of AML cells, as indicated by increased CD14 expression, and induced apoptosis by downregulating anti-apoptotic proteins (Mcl-1, Bcl-XL) while upregulating pro-apoptotic factors (Bak, Bax). Mechanistic studies suggested that Visomitin-induced ROS accumulation enhances AML differentiation and apoptosis. Notably, Visomitin selectively increased ROS in AML cells while reducing ROS levels in normal myeloid cells. Pharmacological and genetic rescue experiments further imply that Visomitin’s anti-AML effects are mediated by ROS-dependent inhibition of SYK. In vivo , Visomitin suppressed tumor growth and elevated ROS within tumors. Furthermore, ex vivo treatment of primary AML cells reduced proliferation, highlighting potential clinical applicability. Conclusion: These findings suggest that Visomitin exerts potent anti-leukemic effects by simultaneously promoting differentiation and apoptosis through ROS-mediated SYK inhibition. The selective activity against malignant cells and favorable in vivo efficacy suggest that Visomitin is a potential therapeutic agent for AML.
- 24 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1741351
Open AccessVisomitin as a differentiation-inducing therapeutic agent through SYK inhibition in AML
Background: Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by the rapid proliferation of immature myeloblasts and resistance to apoptosis. Overcoming the differentiation block and apoptotic resistance remains a major challenge in AML therapy. Visomitin, a mitochondria-targeted antioxidant, has shown protective effects in other contexts, but its potential in AML has not been explored. Methods: We examined the effects of Visomitin on AML cell differentiation and apoptosis using flowcytometry, including CD11b, CD14 staining and ROS measurement. Western blot analysis of Bcl-2 family proteins and p21/p16/Rb axis. Potential underlying mechanisms were explored through SYK activation. Additionally, primary AML patient samples were tested to assess translational relevance, and in vivo efficacy was evaluated in a xenograft mouse model. Results: Treatment with Visomitin promoted differentiation of AML cells, as indicated by increased CD14 expression, and induced apoptosis by downregulating anti-apoptotic proteins (Mcl-1, Bcl-XL) while upregulating pro-apoptotic factors (Bak, Bax). Mechanistic studies suggested that Visomitin-induced ROS accumulation enhances AML differentiation and apoptosis. Notably, Visomitin selectively increased ROS in AML cells while reducing ROS levels in normal myeloid cells. Pharmacological and genetic rescue experiments further imply that Visomitin’s anti-AML effects are mediated by ROS-dependent inhibition of SYK. In vivo , Visomitin suppressed tumor growth and elevated ROS within tumors. Furthermore, ex vivo treatment of primary AML cells reduced proliferation, highlighting potential clinical applicability. Conclusion: These findings suggest that Visomitin exerts potent anti-leukemic effects by simultaneously promoting differentiation and apoptosis through ROS-mediated SYK inhibition. The selective activity against malignant cells and favorable in vivo efficacy suggest that Visomitin is a potential therapeutic agent for AML.
- Open Access
Liver Progenitor Cells: Cellular Origins, Plasticity, and Signaling Pathways in Liver Regeneration
The liver has a notable regenerative capacity, primarily through hepatocyte proliferation. However, when this process is impaired—due to severe and/or chronic injury—liver progenitor cells (LPCs) serve as a facultative reserve to restore hepatic function. LPCs, which are a bipotent and heterogeneous population located near the canals of Hering, can differentiate into hepatocytes and cholangiocytes. Recent evidence suggests that LPCs may originate from mature hepatic cells—such as hepatocytes, cholangiocytes, and hepatic stellate cells—through dedifferentiation under specific injury conditions. Cellular plasticity in the liver is governed by complex signaling networks that regulate LPC activation, maintenance, and lineage commitment. However, the precise cellular origin of LPCs and the mechanisms driving their activation remain incompletely defined. Therefore, this review aims to synthesize current insights into LPC biology and emphasize their diverse cellular origins, functional roles in liver regeneration, and the key signaling pathways involved. A deeper understanding of LPC dynamics may ultimately guide the development of novel therapeutic strategies to enhance liver regeneration in chronic liver disease.
Open AccessLiver Progenitor Cells: Cellular Origins, Plasticity, and Signaling Pathways in Liver Regeneration
The liver has a notable regenerative capacity, primarily through hepatocyte proliferation. However, when this process is impaired—due to severe and/or chronic injury—liver progenitor cells (LPCs) serve as a facultative reserve to restore hepatic function. LPCs, which are a bipotent and heterogeneous population located near the canals of Hering, can differentiate into hepatocytes and cholangiocytes. Recent evidence suggests that LPCs may originate from mature hepatic cells—such as hepatocytes, cholangiocytes, and hepatic stellate cells—through dedifferentiation under specific injury conditions. Cellular plasticity in the liver is governed by complex signaling networks that regulate LPC activation, maintenance, and lineage commitment. However, the precise cellular origin of LPCs and the mechanisms driving their activation remain incompletely defined. Therefore, this review aims to synthesize current insights into LPC biology and emphasize their diverse cellular origins, functional roles in liver regeneration, and the key signaling pathways involved. A deeper understanding of LPC dynamics may ultimately guide the development of novel therapeutic strategies to enhance liver regeneration in chronic liver disease.
- 27 August 2025
- Published by Wiley in Liver International
- Vol. 45 (9) , e70313
Response to Letter to the Editor: “Chronic Nanoplastic Exposure as a Novel Risk Amplifier for MASLD Progression”
- 27 August 2025
- Published by Wiley in Liver International
- Vol. 45 (9) , e70313
Response to Letter to the Editor: “Chronic Nanoplastic Exposure as a Novel Risk Amplifier for MASLD Progression”
- 27 August 2025
- Published by Wiley in Liver International
- Vol. 45 (9) , e70303
Response to Letter to the Editor: ‘Nanoplastics and MASLD : Unveiling Interorgan Crosstalk and Environmental Modulators’
- 27 August 2025
- Published by Wiley in Liver International
- Vol. 45 (9) , e70303
Response to Letter to the Editor: ‘Nanoplastics and MASLD : Unveiling Interorgan Crosstalk and Environmental Modulators’
- Open Access
- 14 July 2025
- Published by Wiley in Liver International
- Vol. 45 (8) , e70224
Chronic Nanoplastic Exposure Promotes the Development and Progression of Metabolic Dysfunction‐Associated Steatotic Liver Disease
Background and Aims: Plastic particles are a global pollution problem, and humans are potentially exposed to them. Ingested plastic particles, microparticles (MPs) and nanoparticles (NPs), predominantly accumulate in the liver and cause hepatotoxicity through oxidative stress and metabolic dysfunction. NPs promote more toxic actions than MPs; however, the mechanisms involved in developing and progressing metabolic dysfunction‐associated steatotic liver disease (MASLD) from chronic exposure to NPs remain poorly understood. Hedgehog (Hh) signalling regulates MASLD pathogenesis. Herein, we investigated the pathophysiological effects of NPs in MASLD.Methods: Mice were orally administered NPs via drinking water while fed a choline‐deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD) for 12 weeks.Results: NPs increased lipid accumulation in hepatocytes and apoptosis. Moreover, these actions were enhanced in lipotoxicity‐exposed hepatocytes. Chronically exposed NPs accumulated in mice livers and aggravated CDAHFD‐induced hepatic damage, especially fibrosis. Activated Hh signalling in the CDAHFD group was elevated by NP treatment. Increased Sonic Hh expression in the hepatocytes of NP‐treated mice in the CDAHFD group triggered Hh signalling in hepatic stellate cells (HSCs), which promoted liver fibrosis.Conclusions: These results demonstrate that chronic exposure to NPs increases vulnerability to MASLD progression, suggesting that NPs are a potentially harmful factor in the development and progression of liver disease.
- 14 July 2025
- Published by Wiley in Liver International
- Vol. 45 (8) , e70224
Open AccessChronic Nanoplastic Exposure Promotes the Development and Progression of Metabolic Dysfunction‐Associated Steatotic Liver Disease
Background and Aims: Plastic particles are a global pollution problem, and humans are potentially exposed to them. Ingested plastic particles, microparticles (MPs) and nanoparticles (NPs), predominantly accumulate in the liver and cause hepatotoxicity through oxidative stress and metabolic dysfunction. NPs promote more toxic actions than MPs; however, the mechanisms involved in developing and progressing metabolic dysfunction‐associated steatotic liver disease (MASLD) from chronic exposure to NPs remain poorly understood. Hedgehog (Hh) signalling regulates MASLD pathogenesis. Herein, we investigated the pathophysiological effects of NPs in MASLD.Methods: Mice were orally administered NPs via drinking water while fed a choline‐deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD) for 12 weeks.Results: NPs increased lipid accumulation in hepatocytes and apoptosis. Moreover, these actions were enhanced in lipotoxicity‐exposed hepatocytes. Chronically exposed NPs accumulated in mice livers and aggravated CDAHFD‐induced hepatic damage, especially fibrosis. Activated Hh signalling in the CDAHFD group was elevated by NP treatment. Increased Sonic Hh expression in the hepatocytes of NP‐treated mice in the CDAHFD group triggered Hh signalling in hepatic stellate cells (HSCs), which promoted liver fibrosis.Conclusions: These results demonstrate that chronic exposure to NPs increases vulnerability to MASLD progression, suggesting that NPs are a potentially harmful factor in the development and progression of liver disease.
- 15 November 2024
- Published by Elsevier in Toxicology
- Vol. 510, 154002
Exposure to polystyrene nanoplastics promotes premature cellular senescence through mitochondrial ROS production and dysfunction in pre-differentiated skeletal myoblasts
- 15 November 2024
- Published by Elsevier in Toxicology
- Vol. 510, 154002
Exposure to polystyrene nanoplastics promotes premature cellular senescence through mitochondrial ROS production and dysfunction in pre-differentiated skeletal myoblasts
- Open Access
- 24 May 2024
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 31 (1) , 1-21
Tumor necrosis factor-inducible gene 6 protein and its derived peptide ameliorate liver fibrosis by repressing CD44 activation in mice with alcohol-related liver disease
Background: Alcohol-related liver disease (ALD) is a major health concern worldwide, but effective therapeutics for ALD are still lacking. Tumor necrosis factor-inducible gene 6 protein (TSG-6), a cytokine released from mesenchymal stem cells, was shown to reduce liver fibrosis and promote successful liver repair in mice with chronically damaged livers. However, the effect of TSG-6 and the mechanism underlying its activity in ALD remain poorly understood. Methods: To investigate its function in ALD mice with fibrosis, male mice chronically fed an ethanol (EtOH)-containing diet for 9 weeks were treated with TSG-6 (EtOH + TSG-6) or PBS (EtOH + Veh) for an additional 3 weeks. Results: Severe hepatic injury in EtOH-treated mice was markedly decreased in TSG-6-treated mice fed EtOH. The EtOH + TSG-6 group had less fibrosis than the EtOH + Veh group. Activation of cluster of differentiation 44 (CD44) was reported to promote HSC activation. CD44 and nuclear CD44 intracellular domain (ICD), a CD44 activator which were upregulated in activated HSCs and ALD mice were significantly downregulated in TSG-6-exposed mice fed EtOH. TSG-6 interacted directly with the catalytic site of MMP14, a proteolytic enzyme that cleaves CD44, inhibited CD44 cleavage to CD44ICD, and reduced HSC activation and liver fibrosis in ALD mice. In addition, a novel peptide designed to include a region that binds to the catalytic site of MMP14 suppressed CD44 activation and attenuated alcohol-induced liver injury, including fibrosis, in mice. Conclusions: These results demonstrate that TSG-6 attenuates alcohol-induced liver damage and fibrosis by blocking CD44 cleavage to CD44ICD and suggest that TSG-6 and TSG-6-mimicking peptide could be used as therapeutics for ALD with fibrosis.
- 24 May 2024
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 31 (1) , 1-21
Open AccessTumor necrosis factor-inducible gene 6 protein and its derived peptide ameliorate liver fibrosis by repressing CD44 activation in mice with alcohol-related liver disease
Background: Alcohol-related liver disease (ALD) is a major health concern worldwide, but effective therapeutics for ALD are still lacking. Tumor necrosis factor-inducible gene 6 protein (TSG-6), a cytokine released from mesenchymal stem cells, was shown to reduce liver fibrosis and promote successful liver repair in mice with chronically damaged livers. However, the effect of TSG-6 and the mechanism underlying its activity in ALD remain poorly understood. Methods: To investigate its function in ALD mice with fibrosis, male mice chronically fed an ethanol (EtOH)-containing diet for 9 weeks were treated with TSG-6 (EtOH + TSG-6) or PBS (EtOH + Veh) for an additional 3 weeks. Results: Severe hepatic injury in EtOH-treated mice was markedly decreased in TSG-6-treated mice fed EtOH. The EtOH + TSG-6 group had less fibrosis than the EtOH + Veh group. Activation of cluster of differentiation 44 (CD44) was reported to promote HSC activation. CD44 and nuclear CD44 intracellular domain (ICD), a CD44 activator which were upregulated in activated HSCs and ALD mice were significantly downregulated in TSG-6-exposed mice fed EtOH. TSG-6 interacted directly with the catalytic site of MMP14, a proteolytic enzyme that cleaves CD44, inhibited CD44 cleavage to CD44ICD, and reduced HSC activation and liver fibrosis in ALD mice. In addition, a novel peptide designed to include a region that binds to the catalytic site of MMP14 suppressed CD44 activation and attenuated alcohol-induced liver injury, including fibrosis, in mice. Conclusions: These results demonstrate that TSG-6 attenuates alcohol-induced liver damage and fibrosis by blocking CD44 cleavage to CD44ICD and suggest that TSG-6 and TSG-6-mimicking peptide could be used as therapeutics for ALD with fibrosis.